PURPOSE: Over the past two decades, there has been significant interest in targeting HER-2/neu in immune-based approaches for the treatment of HER-2/neu+ cancers. For example, peptide vaccination using a CD8 T cell-activating HER-2/neu epitope (amino acids 369-377) is an approach that is being considered in advanced phase clinical trials. Studies have suggested that the persistence of HER-2/neu-specific CD8 T cells could be improved by incorporating human leukocyte antigen (HLA) class II epitopes in the vaccine. Our goal in this study was to identify broad coverage HLA-DR epitopes of HER-2/neu, an antigen that is highly expressed in a variety of carcinomas. EXPERIMENTAL DESIGN: A combination of algorithms and HLA-DR-binding assays was used to identify HLA-DR epitopes of HER-2/neu antigen. Evidence of preexistent immunity in cancer patients against the identified epitopes was determined using IFN-gamma enzyme-linked immunosorbent spot (ELIspot) assay. RESULTS: Eighty-four HLA-DR epitopes of HER-2/neu were predicted, 15 of which had high binding affinity for > or =11 common HLA-DR molecules. A degenerate pool of four HLA-DR-restricted 15-amino acid epitopes (p59, p88, p422, and p885) was identified, against which >58% of breast and ovarian cancer patients had preexistent T-cell immunity. All four epitopes are naturally processed by antigen-presenting cells. Hardy-Weinberg analysis showed that the pool is useful in approximately 84% of population. Lastly, in this degenerate pool, we identified a novel in vivo immunodominant HLA-DR epitope, HER-2/neu(88-102) (p88). CONCLUSION: The broad coverage and natural immunity to this epitope pool suggests potential usefulness in HER-2/neu-targeting, immune-based therapies such as vaccines.
PURPOSE: Over the past two decades, there has been significant interest in targeting HER-2/neu in immune-based approaches for the treatment of HER-2/neu+ cancers. For example, peptide vaccination using a CD8 T cell-activating HER-2/neu epitope (amino acids 369-377) is an approach that is being considered in advanced phase clinical trials. Studies have suggested that the persistence of HER-2/neu-specific CD8 T cells could be improved by incorporating human leukocyte antigen (HLA) class II epitopes in the vaccine. Our goal in this study was to identify broad coverage HLA-DR epitopes of HER-2/neu, an antigen that is highly expressed in a variety of carcinomas. EXPERIMENTAL DESIGN: A combination of algorithms and HLA-DR-binding assays was used to identify HLA-DR epitopes of HER-2/neu antigen. Evidence of preexistent immunity in cancerpatients against the identified epitopes was determined using IFN-gamma enzyme-linked immunosorbent spot (ELIspot) assay. RESULTS: Eighty-four HLA-DR epitopes of HER-2/neu were predicted, 15 of which had high binding affinity for > or =11 common HLA-DR molecules. A degenerate pool of four HLA-DR-restricted 15-amino acid epitopes (p59, p88, p422, and p885) was identified, against which >58% of breast and ovarian cancerpatients had preexistent T-cell immunity. All four epitopes are naturally processed by antigen-presenting cells. Hardy-Weinberg analysis showed that the pool is useful in approximately 84% of population. Lastly, in this degenerate pool, we identified a novel in vivo immunodominant HLA-DR epitope, HER-2/neu(88-102) (p88). CONCLUSION: The broad coverage and natural immunity to this epitope pool suggests potential usefulness in HER-2/neu-targeting, immune-based therapies such as vaccines.
Authors: A Sette; S Buus; E Appella; J A Smith; R Chesnut; C Miles; S M Colon; H M Grey Journal: Proc Natl Acad Sci U S A Date: 1989-05 Impact factor: 11.205
Authors: Mary L Disis; Theodore A Gooley; Kristine Rinn; Donna Davis; Michael Piepkorn; Martin A Cheever; Keith L Knutson; Kathy Schiffman Journal: J Clin Oncol Date: 2002-06-01 Impact factor: 44.544
Authors: S Southwood; J Sidney; A Kondo; M F del Guercio; E Appella; S Hoffman; R T Kubo; R W Chesnut; H M Grey; A Sette Journal: J Immunol Date: 1998-04-01 Impact factor: 5.422
Authors: Constantin N Baxevanis; Panagiota A Sotiropoulou; Nectaria N Sotiriadou; Michael Papamichail Journal: Cancer Immunol Immunother Date: 2003-12-18 Impact factor: 6.968
Authors: Angelos D Gritzapis; Nectaria N Sotiriadou; Michael Papamichail; Constantin N Baxevanis Journal: Cancer Immunol Immunother Date: 2004-05-26 Impact factor: 6.968
Authors: S L Topalian; M I Gonzales; M Parkhurst; Y F Li; S Southwood; A Sette; S A Rosenberg; P F Robbins Journal: J Exp Med Date: 1996-05-01 Impact factor: 14.307
Authors: Evanthia Galanis; Pamela J Atherton; Matthew J Maurer; Keith L Knutson; Sean C Dowdy; William A Cliby; Paul Haluska; Harry J Long; Ann Oberg; Ileana Aderca; Matthew S Block; Jamie Bakkum-Gamez; Mark J Federspiel; Stephen J Russell; Kimberly R Kalli; Gary Keeney; Kah Whye Peng; Lynn C Hartmann Journal: Cancer Res Date: 2014-11-14 Impact factor: 12.701
Authors: Patricio Escalante; Tobias Peikert; Virginia P Van Keulen; Courtney L Erskine; Cathy L Bornhorst; Boleyn R Andrist; Kevin McCoy; Larry R Pease; Roshini S Abraham; Keith L Knutson; Hirohito Kita; Adam G Schrum; Andrew H Limper Journal: Am J Respir Crit Care Med Date: 2015-09-01 Impact factor: 21.405
Authors: Claudia C Preston; Ellen L Goode; Lynn C Hartmann; Kimberly R Kalli; Keith L Knutson Journal: Immunotherapy Date: 2011-04 Impact factor: 4.196
Authors: Håkan Norell; Isabel Poschke; Jehad Charo; Wei Z Wei; Courtney Erskine; Marie P Piechocki; Keith L Knutson; Jonas Bergh; Elisabet Lidbrink; Rolf Kiessling Journal: J Transl Med Date: 2010-06-07 Impact factor: 5.531
Authors: Keith L Knutson; Matthew S Block; Nadine Norton; Courtney L Erskine; Timothy J Hobday; Allan B Dietz; Douglas Padley; Michael P Gustafson; Danell Puglisi-Knutson; Toni Kay Mangskau; Saranya Chumsri; Amylou C Dueck; Lavakumar Karyampudi; Glynn Wilson; Amy C Degnim Journal: Clin Cancer Res Date: 2019-11-22 Impact factor: 12.531